The Medicines Control Authority of Zimbabwe (MCAZ) serves as the centre of national pharmacovigilance in Zimbabwe, overseeing both pharmacovigilance and clinical trials within a defined regulatory framework.

It has implemented various mechanisms for reporting adverse drug reactions, including paper-based and online tools. Active surveillance is carried out for products with known or potential safety concerns.

Annual training sessions are held for healthcare professionals, and patients can report adverse events through multiple channels. A dedicated expert committee reviews all reports to determine appropriate regulatory actions.